12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Livalo pitavastatin: Phase IV data

A double-blind, double-dummy, U.S. Phase IV trial in 252 HIV-infected adults with dyslipidemia with or without viral HBV or HCV infection showed that once-daily 4 mg Livalo met the primary endpoint of reducing LDL-C from baseline to week 12 vs. once-daily 40 mg pravastatin (49.4 vs. 33.6, mg/dL, p<0.001). Additionally, Livalo and pravastatin led to similar increases from baseline to...

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >